Insmed (INSM)
(Delayed Data from NSDQ)
$72.27 USD
+0.87 (1.22%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $72.25 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Company Summary
Bridgewater, NJ-based Insmed is a commercial-stage biopharmaceutical company focused on the development of therapies targeting serious and rare indications.
The FDA granted accelerated approval to Arikayce in 2018 for the treatment of refractory mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in adult patients with limited or no alternative treatment options. The drug is also approved for a similar indication in Europe and Japan.
The most advanced candidate in the company’s pipeline is brensocatib, which is being evaluated in phase III ASPEN as ...
Company Summary
Bridgewater, NJ-based Insmed is a commercial-stage biopharmaceutical company focused on the development of therapies targeting serious and rare indications.
The FDA granted accelerated approval to Arikayce in 2018 for the treatment of refractory mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in adult patients with limited or no alternative treatment options. The drug is also approved for a similar indication in Europe and Japan.
The most advanced candidate in the company’s pipeline is brensocatib, which is being evaluated in phase III ASPEN as a potential treatment for patients with non-cystic fibrosis (non-CF) bronchiectasis. Management plans to submit a regulatory filing with the FDA by the end of 2024. The candidate is also being evaluated in separate clinical studies for other neutrophil-driven inflammatory conditions like chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS).
Apart from brensocatib, treprostinil palmitil inhalation powder (TPIP) is being evaluated in separate mid-stage studies for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH) indications.
In the next few years, Insmed intends to move more preclinical candidates, most of which are gene therapies, towards clinical development as potential treatments for multiple indications like amyotrophic lateral sclerosis (ALS), duchenne muscular dystrophy (DMD) and Stargardt disease.
In 2023, Insmed generated total revenues of $305.2 million, entirely from Arikayce sales. Sales were up 24% year over year.
General Information
Insmed, Inc
700 US Highway 202/206
Bridgewater, NJ 08807
Phone: 908-977-9900
Fax: 732-438-0381
Email: investor.relations@insmed.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | 10/24/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.19 |
Current Year EPS Consensus Estimate | -5.42 |
Estimated Long-Term EPS Growth Rate | 26.60 |
Exp Earnings Date | 10/24/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 71.40 |
52 Week High | 80.53 |
52 Week Low | 21.92 |
Beta | 1.11 |
20 Day Moving Average | 1,880,900.00 |
Target Price Consensus | 85.25 |
4 Week | -2.07 |
12 Week | -7.31 |
YTD | 130.40 |
4 Week | -5.45 |
12 Week | -9.19 |
YTD | 92.80 |
Shares Outstanding (millions) | 171.85 |
Market Capitalization (millions) | 12,270.03 |
Short Ratio | NA |
Last Split Date | 3/3/2011 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -8.99% |
vs. Previous Quarter | -83.02% |
vs. Previous Year | 16.98% |
vs. Previous Quarter | 19.66% |
Price/Book | 273.34 |
Price/Cash Flow | NA |
Price / Sales | 37.34 |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | -57.00 |
3/31/24 | -56.78 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 2.71 |
3/31/24 | 1.80 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 2.53 |
3/31/24 | 1.61 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -243.88 |
3/31/24 | -236.33 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -244.27 |
3/31/24 | -236.74 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -243.37 |
3/31/24 | -235.89 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.26 |
3/31/24 | -3.13 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.88 |
3/31/24 | 0.86 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 25.05 |
3/31/24 | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | 96.16 |
3/31/24 | NA |